1. Home
  2. TENX vs NTRB Comparison

TENX vs NTRB Comparison

Compare TENX & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$10.84

Market Cap

56.2M

Sector

Health Care

ML Signal

HOLD

Logo Nutriband Inc.

NTRB

Nutriband Inc.

N/A

Current Price

$4.30

Market Cap

54.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
NTRB
Founded
1967
2016
Country
United States
United States
Employees
N/A
3
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.2M
54.1M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
TENX
NTRB
Price
$10.84
$4.30
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$22.50
N/A
AVG Volume (30 Days)
181.5K
8.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
96.30
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$30.17
Revenue Next Year
N/A
$3,394.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.64
$3.96
52 Week High
$18.38
$11.68

Technical Indicators

Market Signals
Indicator
TENX
NTRB
Relative Strength Index (RSI) 36.33 49.16
Support Level $5.99 $4.07
Resistance Level $14.15 $4.50
Average True Range (ATR) 0.83 0.23
MACD -0.09 0.01
Stochastic Oscillator 2.33 69.16

Price Performance

Historical Comparison
TENX
NTRB

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Share on Social Networks: